Gerhard Müller studied chemistry at the university of Frankfurt/Main and at the Technical University of Munich, where he received his PhD in 1992 on the medicinal chemistry of anti-adhesive integrin antagonists. From 1992 he worked as computational chemist at Glaxo’s research center in Verona Italy and changed to the Bayer AG in Leverkusen in 1994 where he became project manager within the Central Research Unit. From 2001 to 2003 Gerhard oversaw medicinal chemistry at Organon’s Lead Discovery Unit in Oss, NL. In 2003 he became CSO at Axxima Pharmaceuticals in Munich, and from 2005 to 2007 he held the VP Drug Discovery position at GPC Biotech in Munich. After 3 years at Proteros Fragments, Gerhard established the Medicinal Chemistry business unit at Mercachem in Nijmegen, NL, and since 2017 he is CSO of Gotham Therapeutics in New York and Munich, pioneering the field of small molecule modulators of epitranscriptomic enzymes and receptors.